System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Laurent Machet is an expert in Dermatology at Centre Hospitalier Universitaire de Tours (France). As of September 2026, ScienceLeadR ranks Laurent Machet in the top 1% of experts worldwide for Melanoma, Skin Neoplasms and Sexually Transmitted Diseases. Laurent Machet has authored 395 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 4 of them ongoing. SLR score: 1,049 (community average: 125). How the SLR is computed.

LeadR Profile

Laurent Machet Centre Hospitalier Universitaire de Tours France
1 049 ScienceLeadR Reputation 1049

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1991 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Tours

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 395

Citations

Citations: 16 010 1st author: 49 Last author: 80 Unique author: 4

Main journals

Ann Dermatol Venereol 138
Acta Derm Venereol 36
Br J Dermatol 29
Contact Dermatitis 11
Eur J Dermatol 11

Best Journals

Lancet Oncol 4
N Engl J Med 3
J Clin Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
PMID 42501621 — safety, melanoma, neoplasms, therapeutics, mutation		Eur J Cancer20260
Dermatologists' Attitudes toward Ultrasound-guided One-step Excision for Cutaneous Melanoma: A Survey of Clinical Practice and Perceived Barriers.
PMID 42328998 — sexually transmitted diseases, melanoma, dermatologists, dermatology		Acta Derm Venereol20260
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
PMID 40614118 — cells, safety, incidence, melanoma, neoplasms, carcinoma, renal cell, immune checkpoint inhibitors, nivolumab, ipilimumab		Cancer20250
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.
PMID 40042819 — safety, skin diseases, rituximab, pemphigus		JAMA Dermatol20250
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
PMID 39720605 — sezary syndrome, cohort studies, immunotherapy		EClinicalMedicine20240

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Director: 1

By phase:

Phase 3 10
N/A 7
Phase 2 2

By status:

Completed 10
Recruiting 3
Active not recruiting 2
Unknown 2
Not yet recruiting 1
Terminated 1

By type:

Interventional 14
Observational 5

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 1
multicentric5to9 4
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
Efficacy and Tolerance of THC 25 CBD 25 in Patients With Severe Pruritus a Multicenter Double blind Randomized Placebo controlled Study
NCT06435299 — dronabinol, pain, pruritus, therapeutics		Phase 2Not yet recruiting2027
A Study of Subcutaneous Nivolumab Relatlimab Fixed dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399 — melanoma, nivolumab		Phase 3Active not recruiting2023
Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
NCT05565885 — vasculitis, blood, biomarkers, diagnosis, prognosis		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS